+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

U

Actively Recruiting

Healthy Volunteer

Researchers are conducting a long-term observational study across three microbiology units in hospitals and community health systems in Thailand, Lao PDR, and Cambodia. The study focuses on melioidosis, aiming to understand how the environment, pathogen, and host interact to influence disease development and outcomes. It includes patients diagnosed with melioidosis, matched healthy controls, and residents of a high-risk community known as the Sandbox Village. Patients with melioidosis will be followed at six time points from hospital admission through one year post-discharge to collect clinical data on demographics, medical history, environmental exposures, treatment, adherence, and outcomes. Healthy controls matched by age, sex, and village will provide blood samples at enrollment and receive follow-up calls at 6 and 12 months. The Sandbox Village cohort will involve approximately 400 residents monitored intensively over 42 months, with periodic blood samples collected every two months to assess antibody responses. Participants will undergo various assessments including blood sampling, telephone follow-ups, and clinical data collection. Researchers will measure outcomes such as melioidosis development after exposure, mortality during the acute phase, and hospital readmissions for patients, while controls and community residents will be monitored for subclinical infections and environmental influences. The study spans up to 3.5 years for community participants and one year for patients and controls, with ongoing observation and data collection to better understand melioidosis risks and recovery.

Age: 20Years +All Genders
3 locations
O

Actively Recruiting

Researchers are investigating the optimal dose of tafenoquine for treating Plasmodium vivax malaria in Southeast Asia. This study compares the current recommended 300 mg dose of tafenoquine, which is less effective in this region, to a 50% higher dose. The trial also includes a comparison to high-dose primaquine in Indonesia, where primaquine is the standard care. The goal is to improve radical cure rates by reducing malaria recurrence. Participants will be randomly assigned to receive either the standard tafenoquine dose or a higher dose, both given as a single dose adjusted by weight bands. In Indonesia, a third group will receive high-dose primaquine daily for seven days. All participants will receive a schizonticidal agent such as chloroquine or artemether-lumefantrine alongside tafenoquine or primaquine. Drug administration will be directly observed to ensure adherence, and the treatments are given according to the national malaria guidelines. Participants will be followed daily until malaria parasites clear and then at several scheduled visits up to 4 months. These visits include blood tests, physical exams, and monitoring of adverse events and drug levels. If malaria recurs, treatment and follow-up restart as a new episode. The study measures include recurrence of infection by microscopy and molecular methods, adverse events, and drug levels over time. Data confidentiality and quality control procedures are in place, with a total participation duration of 4 months per episode.

Age: 2Years +All GendersPhase 4
6 locations